Abstract
Treatment of patients with heart failure secondary to myocardial infarction remains a therapeutic challenge. Extensive myocyte death in the heart and post-ischemic remodeling accentuate progressive expansion of the scar area and compromise left ventricular contractile function. The scarcity of resident stem cells in the heart and limited proliferative capacity of adult cardiomyocytes warrant novel strategies of outside intervention to supplement the inept intrinsic repair mechanism. Heart cell therapy using patient's own skeletal muscle derived myoblasts (SkMs) provides a relatively simple and inexpensive therapeutic option. Phase-I and II clinical trials supported by plethora of pre-clinical studies have shown the safety and effectiveness of SkMs engraftment in the treatment of infarcted heart. However, before widespread application of this approach in the clinical settings, there remain some fundamental issues including extensive donor cell death during acute phase after SkMs engraftment, failure of SkMs to adopt cardiac phenotype and transient ventricular arrhythmias subsequent to SkMs transplantation which require serious considerations. This review will provide profound analysis of merits and limitations of SkMs as the choice cells for heart cell therapy and will summarize the potential of genetic and pharmacological manipulation SkMs to enhance their therapeutic efficacy for myocardial repair. Present article also includes recent patent review coverage on this topic.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 205-213 |
| Number of pages | 9 |
| Journal | Recent Patents on Cardiovascular Drug Discovery |
| Volume | 2 |
| Issue number | 3 |
| DOIs | |
| State | Published - Nov 1 2007 |
| Externally published | Yes |
Fingerprint
Keywords
- Cardiac
- Cells
- Heart
- Myocardium
- Skeletal myoblasts
ASJC Scopus subject areas
- Drug Discovery
- Cardiology and Cardiovascular Medicine
- Pharmacology (medical)
Cite this
Skeletal muscle derived stem cells for myocardial repair. / Haider, Husnain K.; Ye, Lei; Ashraf, Muhammad.
In: Recent Patents on Cardiovascular Drug Discovery, Vol. 2, No. 3, 01.11.2007, p. 205-213.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Skeletal muscle derived stem cells for myocardial repair
AU - Haider, Husnain K.
AU - Ye, Lei
AU - Ashraf, Muhammad
PY - 2007/11/1
Y1 - 2007/11/1
N2 - Treatment of patients with heart failure secondary to myocardial infarction remains a therapeutic challenge. Extensive myocyte death in the heart and post-ischemic remodeling accentuate progressive expansion of the scar area and compromise left ventricular contractile function. The scarcity of resident stem cells in the heart and limited proliferative capacity of adult cardiomyocytes warrant novel strategies of outside intervention to supplement the inept intrinsic repair mechanism. Heart cell therapy using patient's own skeletal muscle derived myoblasts (SkMs) provides a relatively simple and inexpensive therapeutic option. Phase-I and II clinical trials supported by plethora of pre-clinical studies have shown the safety and effectiveness of SkMs engraftment in the treatment of infarcted heart. However, before widespread application of this approach in the clinical settings, there remain some fundamental issues including extensive donor cell death during acute phase after SkMs engraftment, failure of SkMs to adopt cardiac phenotype and transient ventricular arrhythmias subsequent to SkMs transplantation which require serious considerations. This review will provide profound analysis of merits and limitations of SkMs as the choice cells for heart cell therapy and will summarize the potential of genetic and pharmacological manipulation SkMs to enhance their therapeutic efficacy for myocardial repair. Present article also includes recent patent review coverage on this topic.
AB - Treatment of patients with heart failure secondary to myocardial infarction remains a therapeutic challenge. Extensive myocyte death in the heart and post-ischemic remodeling accentuate progressive expansion of the scar area and compromise left ventricular contractile function. The scarcity of resident stem cells in the heart and limited proliferative capacity of adult cardiomyocytes warrant novel strategies of outside intervention to supplement the inept intrinsic repair mechanism. Heart cell therapy using patient's own skeletal muscle derived myoblasts (SkMs) provides a relatively simple and inexpensive therapeutic option. Phase-I and II clinical trials supported by plethora of pre-clinical studies have shown the safety and effectiveness of SkMs engraftment in the treatment of infarcted heart. However, before widespread application of this approach in the clinical settings, there remain some fundamental issues including extensive donor cell death during acute phase after SkMs engraftment, failure of SkMs to adopt cardiac phenotype and transient ventricular arrhythmias subsequent to SkMs transplantation which require serious considerations. This review will provide profound analysis of merits and limitations of SkMs as the choice cells for heart cell therapy and will summarize the potential of genetic and pharmacological manipulation SkMs to enhance their therapeutic efficacy for myocardial repair. Present article also includes recent patent review coverage on this topic.
KW - Cardiac
KW - Cells
KW - Heart
KW - Myocardium
KW - Skeletal myoblasts
UR - http://www.scopus.com/inward/record.url?scp=36749003419&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36749003419&partnerID=8YFLogxK
U2 - 10.2174/157489007782418955
DO - 10.2174/157489007782418955
M3 - Review article
VL - 2
SP - 205
EP - 213
JO - Recent Patents on Cardiovascular Drug Discovery
JF - Recent Patents on Cardiovascular Drug Discovery
SN - 1574-8901
IS - 3
ER -